Detalhe da pesquisa
1.
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
Haematologica
; 109(3): 895-905, 2024 Mar 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37646660
2.
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study.
Haematologica
; 2024 Feb 29.
Artigo
Inglês
| MEDLINE | ID: mdl-38426292
3.
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.
Eur J Haematol
; 112(3): 402-411, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-37968873
4.
Gastrointestinal cancer precursor risk and mortality in pancreatic intraductal papillary mucinous neoplasms: a nationwide cohort study.
Scand J Gastroenterol
; 59(5): 600-607, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38351653
5.
Progression of Enteral Feeding Volumes in Extremely Low Birth Weight Infants in the "Connection Trial".
Am J Perinatol
; 2023 Sep 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37683670
6.
Patients with type 1 and type 2 diabetes hospitalized with COVID-19 in comparison with influenza: mortality and cardiorenal complications assessed by nationwide Swedish registry data.
Cardiovasc Diabetol
; 21(1): 282, 2022 12 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36522650
7.
Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries.
Diabetes Obes Metab
; 24(7): 1277-1287, 2022 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35322567
8.
Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data.
Cardiovasc Diabetol
; 20(1): 159, 2021 07 31.
Artigo
Inglês
| MEDLINE | ID: mdl-34332558
9.
Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
Diabetes Obes Metab
; 23 Suppl 2: 19-27, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33835641
10.
Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study.
Diabetes Obes Metab
; 23(6): 1431-1435, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33606906
11.
Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.
Diabetes Obes Metab
; 23(1): 75-85, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32893440
12.
Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence.
Diabetes Obes Metab
; 22(12): 2364-2374, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32744392
13.
Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study.
Diabetes Obes Metab
; 22(9): 1607-1618, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32363737
14.
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
Cardiovasc Diabetol
; 18(1): 138, 2019 10 22.
Artigo
Inglês
| MEDLINE | ID: mdl-31640705
15.
Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study.
Diabetes Obes Metab
; 21(12): 2651-2659, 2019 12.
Artigo
Inglês
| MEDLINE | ID: mdl-31379124
16.
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study.
Diabetes Obes Metab
; 21(5): 1136-1145, 2019 05.
Artigo
Inglês
| MEDLINE | ID: mdl-30609272
17.
How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study.
Diabetes Obes Metab
; 21(4): 968-974, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30537226
18.
Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study.
Circulation
; 136(13): 1183-1192, 2017 Sep 26.
Artigo
Inglês
| MEDLINE | ID: mdl-28947478
19.
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Circulation
; 136(3): 249-259, 2017 Jul 18.
Artigo
Inglês
| MEDLINE | ID: mdl-28522450
20.
Prevalence, characteristics and management of frequently exacerbating asthma patients: an observational study in Sweden (PACEHR).
Eur Respir J
; 52(2)2018 08.
Artigo
Inglês
| MEDLINE | ID: mdl-29946008